Theravance Climbs as COPD Program Enters Phase III
By Marie Powers
Friday, February 4, 2011
GlaxoSmithKline plc and Theravance Inc. achieved major milestones this week in a pair of clinical development programs focused on treatments for patients with chronic obstructive pulmonary disease (COPD).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.